Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNCE Concert Pharmaceuticals	$8.37	$8.37	$2.66 ▼ $8.55	$401.26M	0.52	2.97 million shs	N/A
CTMX CytomX Therapeutics	$2.60 +4.4%	$2.20	$0.40 ▼ $3.10	$200.75M	2.05	2.21 million shs	3.71 million shs
CXRXF ADVANZ PHARMA	$17.06	$17.06	$2.13 ▼ $18.00	$834.46M	N/A	11,851 shs	39 shs
EOLS Evolus	$9.73 +0.7%	$9.81	$8.67 ▼ $17.82	$622.83M	0.97	761,589 shs	555,550 shs
SPPI Spectrum Pharmaceuticals	$1.03	$1.01	$0.32 ▼ $1.57	$211.41M	2.15	1.93 million shs	N/A

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNCE Concert Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
CTMX CytomX Therapeutics	+3.75%	+0.40%	-5.32%	+403.44%	+84.44%
CXRXF ADVANZ PHARMA	0.00%	0.00%	0.00%	0.00%	0.00%
EOLS Evolus	+4.32%	+4.89%	+0.10%	+2.66%	-13.52%
SPPI Spectrum Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CNCE Concert Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	4.2022 of 5 stars	3.5	1.0	0.0	4.7	2.1	1.7	1.3
CXRXF ADVANZ PHARMA	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EOLS Evolus	3.9225 of 5 stars	3.5	0.0	0.0	3.5	2.3	3.3	0.6
SPPI Spectrum Pharmaceuticals	0.5506 of 5 stars	0.0	0.0	0.0	4.7	0.6	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNCE Concert Pharmaceuticals	0.00	N/A	N/A	N/A
CTMX CytomX Therapeutics	3.00	Buy	$5.33	105.13% Upside
CXRXF ADVANZ PHARMA	0.00	N/A	N/A	N/A
EOLS Evolus	3.00	Buy	$23.75	144.09% Upside
SPPI Spectrum Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest EOLS, CTMX, CNCE, SPPI, and CXRXF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$2.50 ➝ $5.00
5/15/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $5.00
5/12/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00 ➝ $6.00
5/8/2025	EOLS Evolus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00
4/17/2025	EOLS Evolus	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00
4/14/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$3.25 ➝ $2.50
4/10/2025	EOLS Evolus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $27.00

(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNCE Concert Pharmaceuticals	$32.58M	12.32	N/A	N/A	$3.24 per share	2.58
CTMX CytomX Therapeutics	$138.10M	1.52	$0.38 per share	6.88	($0.01) per share	-260.00
CXRXF ADVANZ PHARMA	$525.58M	1.59	N/A	N/A	$0.16 per share	106.63
EOLS Evolus	$266.27M	2.36	N/A	N/A	$0.09 per share	108.11
SPPI Spectrum Pharmaceuticals	$10.11M	20.91	N/A	N/A	$0.15 per share	6.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNCE Concert Pharmaceuticals	-$80.05M	-$3.21	N/A	N/A	N/A	N/A	-109.43%	-76.65%	N/A
CTMX CytomX Therapeutics	$31.87M	$0.48	5.42	N/A	N/A	28.22%	-553.71%	32.21%	8/14/2025 (Estimated)
CXRXF ADVANZ PHARMA	-$74.86M	N/A	N/A	∞	N/A	-15.31%	N/A	-4.38%	N/A
EOLS Evolus	-$50.42M	-$0.89	N/A	N/A	N/A	-20.40%	-759.04%	-20.14%	7/30/2025 (Estimated)
SPPI Spectrum Pharmaceuticals	-$75.40M	-$0.36	N/A	14.71	N/A	N/A	-218.44%	-66.16%	N/A

Latest EOLS, CTMX, CNCE, SPPI, and CXRXF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
7/30/2025	Q2 2025	EOLS Evolus	-$0.09	N/A	N/A	N/A	$82.18 million	N/A
5/12/2025	Q1 2025	CTMX CytomX Therapeutics	$0.18	$0.27	+$0.09	$0.27	$35.42 million	$50.92 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNCE Concert Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
CXRXF ADVANZ PHARMA	N/A	N/A	N/A	N/A	N/A
EOLS Evolus	N/A	N/A	N/A	N/A	N/A
SPPI Spectrum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNCE Concert Pharmaceuticals	N/A	9.03	9.03
CTMX CytomX Therapeutics	N/A	1.73	1.73
CXRXF ADVANZ PHARMA	257.04	2.39	1.61
EOLS Evolus	22.00	2.34	2.16
SPPI Spectrum Pharmaceuticals	N/A	2.71	2.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNCE Concert Pharmaceuticals	70.63%
CTMX CytomX Therapeutics	67.77%
CXRXF ADVANZ PHARMA	N/A
EOLS Evolus	90.69%
SPPI Spectrum Pharmaceuticals	21.67%

Insider Ownership

Company	Insider Ownership
CNCE Concert Pharmaceuticals	11.33%
CTMX CytomX Therapeutics	6.60%
CXRXF ADVANZ PHARMA	N/A
EOLS Evolus	5.90%
SPPI Spectrum Pharmaceuticals	2.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNCE Concert Pharmaceuticals	64	47.94 million	42.51 million	Optionable
CTMX CytomX Therapeutics	170	80.62 million	75.30 million	Optionable
CXRXF ADVANZ PHARMA	429	48.91 million	N/A	Not Optionable
EOLS Evolus	170	64.48 million	60.67 million	Optionable
SPPI Spectrum Pharmaceuticals	86	205.25 million	199.70 million	Optionable

EOLS, CTMX, CNCE, SPPI, and CXRXF Headlines

Recent News About These Companies

IDMC Provides Positive Recommendation for Bio-Thera Solution's BAT4406F (ADCC-Enhanced Anti-CD20 mAb) in Neuromyelitis Optica Spectrum Disorder Based on Interim Analysis of Pivotal Phase II/III Trial

July 2, 2025 | prnewswire.com

Pneumagen Announces Peer-Reviewed Publication of Positive Phase II Study Data Highlighting the Potential of Neumifil, a Novel Broad-Spectrum Antiviral

July 2, 2025 | globenewswire.com

There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate

July 1, 2025 | accessnewswire.comA

Osivax Announces Last Patient Last Visit in Phase 2a Trial Evaluating a Booster Dose of Broad-Spectrum Influenza Vaccine OVX836 s release

June 5, 2025 | globenewswire.com

Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo

May 8, 2025 | accessnewswire.comA

Bio-Thera Solutions Publishes Phase I Clinical Study Results for BAT4406F, an ADCC-Enhanced Fully Humanized Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum Disorders

January 14, 2025 | prnewswire.com

Non-Hodgkin’s Lymphoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

November 4, 2024 | theglobeandmail.com

Spectrum Thin Films, Inc.

October 31, 2024 | optics.orgO

India – Key Considerations For Patenting Nutraceuticals/Dietary Supplements.

October 10, 2024 | conventuslaw.comC

Qylur Awarded SBIR Phase II Contract for a Tactical AI Spectrum Classifier Systems (TASCS)

October 2, 2024 | globenewswire.com

NanoViricides prepares for Phase II trial of broad-spectrum antiviral NV-387

August 19, 2024 | proactiveinvestors.com

GPC Biotech Announces Granting of European Patent Related to Satraplatin for Treating Tumors Resistant or Refractory to Taxanes

August 19, 2024 | br.advfn.com

Global AL Amyloidosis Therapeutics Market Set for Remarkable Growth, Projected to Reach USD 4.56 Billion by 2033

July 31, 2024 | fmiblog.comF

Company History - Paam Drugs and Pharmaceuticals

July 19, 2024 | moneycontrol.com

STALICLA publishes pioneering phase 1b data on precision treatment for autism spectrum disorder in Biomedicines

June 27, 2024 | globenewswire.com

Osivax Completes Enrollment for Phase 1 Trial with Broad-Spectrum Sarbecovirus Vaccine Candidate, OVX033

June 25, 2024 | businesswire.com

Pneumagen Presents Positive Phase 2 Influenza Human Challenge Study data on Neumifil, its Broad-Spectrum Antiviral Drug, at the American Thoracic Society (ATS) 2024 Conference

May 23, 2024 | globenewswire.com

Pneumagen to Present Phase 2 Clinical Data on Neumifil, its Broad-Spectrum Antiviral, Intranasal Drug for Viral Respiratory Tract Infections, at ATS 2024

May 2, 2024 | globenewswire.com

Spectrum Pharmaceuticals gets grant for crystalline form of quinazoline compound and hydrochloride salts

April 24, 2024 | pharmaceutical-technology.comP

Assertio Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information - ASRT

February 21, 2024 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EOLS, CTMX, CNCE, SPPI, and CXRXF Company Descriptions

Concert Pharmaceuticals NASDAQ:CNCE

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

CytomX Therapeutics NASDAQ:CTMX

$2.60 +0.11 (+4.42%)

Closing price 04:00 PM Eastern

Extended Trading

$2.57 -0.03 (-1.15%)

As of 07:59 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

ADVANZ PHARMA OTCMKTS:CXRXF

$17.06 0.00 (0.00%)

As of 06/10/2021

ADVANZ PHARMA Corp. Limited, a pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products worldwide. The company operates through two segments: ADVANZ PHARMA International and ADVANZ PHARMA North America. Its ADVANZ PHARMA International segment offers a portfolio of branded and generic prescription products to wholesalers, distributors, hospitals, and pharmacies. This segment's products include Brinavess for the conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome; Xydalba, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections in adults; and Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired and hospital-acquired pneumonia. The company's ADVANZ PHARMA North America segment provides Donnatal for the treatment of irritable bowel syndrome; Zonegran for the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Lanoxin for the treatment of mild to moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; and Photofrin for the treatment of certain types of cancer. It also offers Prostaglandin E1 formulations for the treatment of erectile dysfunction and peripheral arterial occlusive disease under the Prostavasin, Viridal, Vasaprostan, and Edex brands, as well as holds licensed commercialization rights to a pre-registration drug/device combination product, Trevyent for the treatment of pulmonary arterial hypertension. It sells its products through direct sales and local distribution relationships. The company was formerly known as ADVANZ PHARMA Corp. and changed its name to ADVANZ PHARMA Corp. Limited in December 2019. ADVANZ PHARMA Corp. Limited is headquartered in London, the United Kingdom.

Evolus NASDAQ:EOLS

$9.73 +0.07 (+0.72%)

Closing price 04:00 PM Eastern

Extended Trading

$9.80 +0.07 (+0.77%)

As of 07:55 PM Eastern

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Spectrum Pharmaceuticals NASDAQ:SPPI

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time